Dangers of outpatient nimodipine use after spontaneous subarachnoid hemorrhage in accordance with the Comprehensive Stroke Center guidelines

This report underscores the danger of outpatient nimodipine use and questions the optimal length of nimodipine therapy, especially in patients with low risk of vasospasm. Future studies, including randomized controlled trials and cost-effectiveness studies, are necessary to clarify the benefit of 21-day nimodipine therapy compared to a shortened duration of nimodipine.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research